Ney Carter Borges: Evaluating the True Symptomatic Benefit of PCI in Patients with CTO and Stable Angina
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“ORBITA-CTO Trial — ACC 26
The ORBITA-CTO trial is the first randomized, double-blind, placebo – controlled study evaluating the true symptomatic benefit of percutaneous coronary intervention (PCI) in patients with chronic total occlusion (CTO) and stable angina.
Study Design
This multicenter UK trial randomized 50 patients with single-vessel CTO, documented ischemia, and viable myocardium to either:
- CTO PCI (n=25)
- Placebo procedure (n=25)
A rigorous blinding strategy was implemented using sedation and procedural simulation.
Anti-anginal therapy was withdrawn at randomization and reintroduced as needed.
Patients were followed for 6 months, with daily symptom tracking via a smartphone app (ORBITA-app).
Primary Outcome
The primary endpoint was a composite angina symptom score, integrating:
- Daily angina frequency
- Anti-anginal medication use
- Clinical escalation events
Key Results
CTO PCI significantly improved angina compared with placebo:
- OR 4.38 (95% CrI 1.57–12.69; probability of benefit = 0.996)
Reduction in angina episodes was the main driver:
- OR 4.38 (95% CrI 1.55–11.78)
Patients undergoing PCI experienced:
- Plus 30.6 additional angina-free days over 6 months
Secondary Outcomes
Consistent improvements were observed in:
Seattle Angina Questionnaire (SAQ):
Angina frequency: +10.7 points
Physical limitation: +13.5 points
Quality of life: +18.2 points
Summary score: +13.7 points
CCS angina class improved significantly
No meaningful benefit was seen in:
- Dyspnea (NYHA, RDS)
- Generic QoL (EQ-5D)
Interpretation
This trial provides definitive placebo-controlled evidence that:
- CTO PCI yields a true physiological reduction in angina, not merely placebo effect
- The magnitude of benefit is moderate but clinically meaningful
- Symptom improvement is immediate and sustained
Importantly, a substantial placebo effect was also observed, reinforcing the need for blinded trials in interventional cardiology.
Clinical Implications
- CTO PCI should be considered for symptomatic patients with demonstrable ischemia, especially in expert centers
- Patient selection and shared decision-making remain critical
- Benefits are primarily symptomatic, with no evidence for prognostic improvement
Take-Home Message
ORBITA-CTO establishes CTO PCI as an effective therapy for angina relief beyond placebo, with robust methodological validation – reshaping the evidence base for complex coronary revascularization.”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow